Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
New Microbes and New Infections|March 19, 2026
Amikacin exposure in MDR-TB patients in Uganda: Revisiting old drugs in a new era of resistance - A pharmacokinetic assessmentJan Hongler, Sabine Haller, Akello Susan Adakun, et al.
The International Journal of Neuropsychopharmacology|May 5, 2007
Novel mutations of the extraneuronal monoamine transporter gene in children and adolescents with obsessive-compulsive disorderAndreas Lazar, Susanne Walitza, Alexander Jetter, et al.
Clinical Pharmacology and Therapeutics|December 21, 2006
Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotypeJulia Kirchheiner, Soju Thomas, Steffen Bauer, et al.
Frontiers in Medicine|November 5, 2019
Danger of Herbal Tea: A Case of Acute Cholestatic Hepatitis Due to <i>Artemisia annua</i> TeaFrancisco Javier Ruperti-Repilado, Simon Haefliger, Sophia Rehm, et al.
Clinical Pharmacokinetics|March 23, 2007
Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicityStefan Wilde, Alexander Jetter, Stephan Rietbrock, et al.
Cancer Chemotherapy and Pharmacology|March 11, 2020
Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patientsUsman Arshad, Su-Arpa Ploylearmsaeng, Mats O Karlsson, et al.
Journal of Crohn'S & Colitis|August 14, 2012
Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis - an open pilot studyLuc Biedermann, Jessica Mwinyi, Michael Scharl, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 27, 2011
Oral supplementation with 25(OH)D3 versus vitamin D3: effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunityHeike Annette Bischoff-Ferrari, Bess Dawson-Hughes, Elisabeth Stöcklin, et al.
European Journal of Clinical Pharmacology|March 27, 2004
Cytochrome P450 2C9 phenotyping using low-dose tolbutamideAlexander Jetter, Martina Kinzig-Schippers, Andreas Skott, et al.
BMC Cancer|October 21, 2016
Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trialPerparim Limani, Michael Linecker, Philipp Kron, et al.
Pageof 6